Skip to main navigation Skip to search Skip to main content

Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections

  • Ahran Lee
  • , Jung Sik Yoo
  • , Eun Jeong Yoon
  • Korea National Institute of Health

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Clostridioides difficile is a major causative pathogen for antibiotic-associated diarrhea and C. difficile infections (CDIs) may lead to life-threatening diseases in clinical settings. Most of the risk factors for the incidence of CDIs, i.e., antibiotic use, treatment by proton pump inhibitors, old age, and hospitalization, are associated with dysbiosis of gut microbiota and associated metabolites and, consequently, treatment options for CDIs include normalizing the composition of the intestinal microbiome. In this review, with an introduction to the CDI and its global epidemiology, CDI-associated traits of the gut microbiome and its metabolites were reviewed, and microbiome-targeting treatment options were introduced, which was approved recently as a new drug by the United States Food and Drug Administration (U.S. FDA), rather than a medical practice.

Original languageEnglish
Article number995
JournalAntibiotics
Volume13
Issue number10
DOIs
StatePublished - Oct 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clostridioides diffcile
  • Clostridioides diffcile infections
  • gut microbiota dysbiosis
  • microbiota-based therapeutics

Fingerprint

Dive into the research topics of 'Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections'. Together they form a unique fingerprint.

Cite this